• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Verastem

Illustration for Fierces Chutes  Ladders feature showing a blue city skyline with executives making career moves o
Biotech

AC Immune CEO bids adieu—Chutes & Ladders

AC Immune CEO bids adieu. Bicara picks up commercial head from Replimune. Infinimmune names CMO to lead clinical push.
Darren Incorvaia , Zoey Becker , Will Maddox May 15, 2026 8:30am
An artists illustration of a KRAS G12C mutation in non-small cell lung cancer

AACR: KRAS inhibitors pop in preclinical data debuts

Apr 11, 2024 4:30am
mergers  acquisitions

Verastem bags options on GenFleet RAS programs to grow pipeline

Aug 28, 2023 10:30am
close-up of money

Verastem takes on debt to get RAS tumor program to finish line

Mar 28, 2022 8:30am
Immuno-oncology

Verastem CMO quits 2 weeks into the job

Jan 20, 2021 9:50am
Boston Massachusetts

Verastem pens KRAS-focused drug licensing deal with Chugai

Jan 8, 2020 9:20am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings